Alzheimer’s Drug Discovery Foundation – Calls
Prevention
The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
More details : https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-pipeline
Neuroimaging and CSF Biomarker Program
The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.
More details: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers
Drug Development RFP
The Drug Development RFP supports investigational new drug (IND)-enabling studies (or the international equivalent) and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.
More details: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-rfp